Cowen Remains Bullish on XOMA (XOMA) Ahead of EYEGUARD-B Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
UPDATE: XOMA (XOMA) Gains in Anticipation of Positive Gevokizumab Data
July 9, 2015 11:32 AM EDT(Updated - July 9, 2015 11:56 AM EDT)
XOMA (NASDAQ: XOMA) shares jumped late Thursday morning as traders positioned in anticipation of Gevokizumab phase III EYEGUARD-B data in Behcets Disease. The data is expected "imminently," said RBC Capital's Adnan Butt in research... More
